Results 1 to 10 of about 935,464 (264)

Therapeutic Antibodies in Medicine [PDF]

Molecules, 2023
Antibody engineering has developed into a wide-reaching field, impacting a multitude of industries, most notably healthcare and diagnostics. The seminal work on developing the first monoclonal antibody four decades ago has witnessed exponential growth in
Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu, Maya A. Eicher   +4 more
doaj   +4 more sources

Antibody Engineering for the Development of Therapeutic Antibodies

Molecules and Cells, 2005
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical ...
Hyo Jeong Hong, Sang Jick Kim
exaly   +3 more sources

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model

Frontiers in Oncology, 2022
DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment.
Kevin Hollevoet, Kevin Hollevoet, Debby Thomas, Debby Thomas, Griet Compernolle, Griet Compernolle, Giles Vermeire, Elien De Smidt, Elien De Smidt, Stéphanie De Vleeschauwer, Trevor R. F. Smith, Paul D. Fisher, Maarten Dewilde, Maarten Dewilde, Nick Geukens, Paul Declerck, Paul Declerck   +16 more
doaj   +1 more source

Editorial: The immune response to therapeutic antibodies [PDF]

Frontiers in Immunology
Michael G. Tovey, Arno J. Kromminga, Daniel T. Mytych   +2 more
doaj   +2 more sources

Extreme Point Sort Transformation Combined With a Long Short-Term Memory Network Algorithm for the Raman-Based Identification of Therapeutic Monoclonal Antibodies

Frontiers in Chemistry, 2022
Therapeutic monoclonal antibodies (mAbs) are a new generation of protein-based medicines that are usually expensive and thus represent a target for counterfeiters.
Jin Ling, Luxia Zheng, Mingming Xu, Gang Chen, Xiao Wang, Danzhuo Mao, Hong Shao   +6 more
doaj   +1 more source

Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab

Frontiers in Chemistry, 2022
Succinimide (Asu) is the intermediate for asparagine deamidation in therapeutic proteins, and it can be readily hydrolyzed to form aspartate and iso-aspartate residues. Moreover, Asu plays an important role in the protein degradation pathways, asparagine
Tao Liu, Tao Liu, Tao Liu, Jin Xu, Jin Xu, Jin Xu, Jin Xu, Qingcheng Guo, Dapeng Zhang, Dapeng Zhang, Dapeng Zhang, Jun Li, Weizhu Qian, Weizhu Qian, Weizhu Qian, Huaizu Guo, Huaizu Guo, Huaizu Guo, Huaizu Guo, Xinli Zhou, Sheng Hou, Sheng Hou, Sheng Hou   +22 more
doaj   +1 more source

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Pharmaceutics, 2023
The blood-brain barrier (BBB), while being the gatekeeper of the central nervous system (CNS), is a bottleneck for the treatment of neurological diseases.
Laura Rué, Tom Jaspers, Isabelle M. S. Degors, Sam Noppen, Dominique Schols, Bart De Strooper, Maarten Dewilde   +6 more
doaj   +1 more source

Non-fucosylated Therapeutic Antibodies: The Next Generation of Therapeutic Antibodies [PDF]

Cytotechnology, 2007
Therapeutic antibody IgG1 has two N-linked oligosaccharide chains bound to the Fc region. The oligosaccharides are of the complex biantennary type, composed of a trimannosyl core structure with the presence or absence of core fucose, bisecting N-acetylglucosamine (GlcNAc), galactose, and terminal sialic acid, which gives rise to structural ...
Katsuhiro, Mori, Shigeru, Iida, Naoko, Yamane-Ohnuki, Yutaka, Kanda, Reiko, Kuni-Kamochi, Ryosuke, Nakano, Harue, Imai-Nishiya, Akira, Okazaki, Toyohide, Shinkawa, Akihito, Natsume, Rinpei, Niwa, Kenya, Shitara, Mitsuo, Satoh   +12 more
openaire   +2 more sources

Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles

Biosafety and Health, 2022
The coronavirus disease 2019 (COVID-19) is still causing a wide range of infections and deaths due to the high variability of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Sheng Wang, Lizhen Liu, Can Wang, Ziqiang Wang, Xuhua Duan, Gang Chen, Hu Zhou, Hong Shao   +7 more
doaj   +1 more source

Optimization of therapeutic antibodies [PDF]

Antibody Therapeutics, 2021
AbstractIn this review, we have summarized the current landscape of therapeutic antibody optimization for successful development. By engineering antibodies with display technology, computer-aided design and site mutagenesis, various properties of the therapeutic antibody candidates can be improved with the purpose of enhancing their safety, efficacy ...
Bo Wang, Sachith Gallolu Kankanamalage, Jianbo Dong, Yue Liu   +3 more
openaire   +2 more sources